Online inquiry

IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6543MR)

This product GTTS-WQ6543MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Uveitis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6543MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4599MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ492MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ8896MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ3398MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA aALB03
GTTS-WQ4157MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ12558MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ15010MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ4615MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW